Developer docs
API playgroundTry for free, no card

Search company profiles

Corxel Pharmaceuticals

Full company profile

uuid0037k8o

Namestring
Corxel Pharmaceuticals
Legal namestring
Corxel Pharmaceuticals (Shanghai) Co., Ltd. (箕星药业科技(上海)有限公司)
Websiteurl
corxelbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2019 by RTW Investments and headquartered in Berkeley Heights, New Jersey, with operational offices in Shanghai, Hong Kong, Beijing, and Denmark. The company is developing oral small-molecule therapies for cardiometabolic diseases — the leading global cause of death and disability — with a pipeline spanning obesity/overweight, type 2 diabetes mellitus (T2DM), acute ischemic stroke (AIS), and hypertension.

The core proprietary asset is CX11 (VCT220), an oral small-molecule GLP-1 receptor agonist licensed ex-China from Vincentage Pharma in December 2024. CX11 is designed for once-daily administration without food/water restrictions or cold-chain storage, demonstrated 11.5% body weight reduction at 36 weeks in a 246-patient U.S. Phase 2 trial and 12.2–12.4% at 52 weeks in a 840-patient China Phase 3, with favorable GI tolerability and no hepatic safety signal across 1,500+ participants. The pipeline also includes JX10 (formerly BIIB131), a plasminogen modulator licensed from Biogen in January 2024 in a global Phase 2/3 registrational trial for AIS that extends the treatment window from the standard 4.5-hour t-PA limit to 4.5–24 hours from last known well, plus preclinical CX12 (oral amylin receptor agonist) and JX09 (aldosterone synthase inhibitor for hypertension). The cardiometabolic focus has been sharpened by divesting non-core Greater China rights to CARDAMYST (etripamil, to Everest Medicines, March 2026, $30M upfront plus $20M milestones) and LNZ100/VIZZ (presbyopia, to Everest Medicines, June 2026, up to $85M in milestones plus royalties).

The business model is licensing-and-development rather than commercial sales: the company is pre-revenue with no approved products, monetizing assets through upfront and milestone payments from regional partners (Everest Medicines for Greater China commercialization of in-licensed assets) while retaining global rights to its proprietary pipeline for future commercialization or strategic partnership. Capital is sourced from a syndicate of healthcare-specialist investors including RTW Investments (founder), Bayer ($35M equity, January 2024, with privileged CV/ophthalmology negotiation rights), and a $287M Series D1 (January 2026) led by SR One and TCGX with participation from RA Capital, HBM Healthcare Investments, and others. Leadership brings direct lineage to the GLP-1 franchise: CMO Bo Liang led global clinical development of Semaglutide and Icodec at Novo Nordisk, and CFO Kevin Xie previously led Gracell Biotechnologies through its Nasdaq IPO and $1.2B AstraZeneca acquisition.

Short descriptiontext

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for cardiometabolic diseases — including CX11 (oral GLP-1 RA for obesity/T2DM) and JX10 (plasminogen modulator for acute ischemic stroke) — serving global patient populations via a tri-regional US/China/Europe development platform backed by RTW Investments and Bayer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerkeley Heights, United States
HQ citystring
Berkeley Heights
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, cardiometabolic disease therapies, oral small molecule drugs, GLP-1 receptor agonists, acute ischemic stroke treatment
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cardiometabolic Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Licensing and Asset Monetization
TypeLicensing Royalties
Description

CORXEL generates near-term value through licensing and asset sale transactions. The company sold Greater China rights to LNZ100/VIZZ to Everest Medicines (June 2026) and CARDAMYST to Everest Medicines (March 2026), receiving upfront payments and milestone payments. This model funds the global development of its proprietary cardiometabolic pipeline.

corxelbio.com
2Future Product Sales (Pre-Revenue)
TypeSubscription Recurring
Description

CORXEL is a clinical-stage biopharma with no current product revenue. Its proprietary pipeline (CX11 for obesity/T2DM, JX10 for AIS, CX12 in preclinical) is under development globally, with plans to commercialize upon regulatory approval. The company is backed by $287M Series D1 financing to fund development costs.

corxelbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule therapies for cardiometabolic diseases. Its lead asset CX11 is an oral GLP-1 receptor agonist for obesity, overweight, and Type 2 Diabetes, supported by Phase 2 U.S. and Phase 3 China data. The company also advances JX10, a thrombolytic/anti-inflammatory agent for acute ischemic stroke, and preclinical candidates CX12 (oral amylin RA) and JX09 (aldosterone synthase inhibitor) for hypertension.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 11.5% body weight reduction at 36 weeks with CX11 (120–200 mg daily oral) in 246 U.S. Phase 2 trial participants with obesity/overweight
+4 more records
Product overview1 text field

CORXEL is a clinical-stage biopharmaceutical company developing a portfolio of oral small molecule compounds for cardiometabolic diseases. The core pipeline includes CX11 (oral GLP-1 RA for obesity, overweight, and T2DM), JX10 (thrombolytic agent for acute ischemic stroke), CX12 (amylin RA in preclinical stage), and JX09 (aldosterone synthase inhibitor for hypertension). The company previously held rights to LNZ100/VIZZ (presbyopia treatment) and CARDAMYST (etripamil, PSVT treatment) which were sold to Everest Medicines, allowing CORXEL to focus entirely on its cardiometabolic pipeline.

Product and service4 records
1CX11 (VCT220)
CategoryOral GLP-1 Receptor Agonist
Description

Investigational oral small molecule GLP-1 receptor agonist designed for once-daily administration in adults with obesity, overweight with comorbidities, and Type 2 Diabetes Mellitus. Licensed worldwide ex-Greater China from Vincentage Pharma in December 2024.

2JX10 (formerly BIIB131)
CategoryThrombolytic / Anti-inflammatory Agent
Description

Investigational plasminogen modulator with thrombolytic, anti-inflammatory, and antioxidative activities for acute ischemic stroke (AIS), designed to extend the treatment window from the standard 4.5 hours to 4.5–24 hours from last known well. Licensed globally excluding Japan from Biogen.

3CX12
CategoryOral Amylin Receptor Agonist
Description

Investigational oral small molecule amylin receptor agonist in preclinical development for obesity. Designed to regulate satiety, slow gastric emptying, and suppress post-prandial glucagon, with advantages in stability, manufacturing cost, and cold-chain-free storage versus peptide amylin agonists.

4JX09
CategoryAldosterone Synthase Inhibitor
Description

Highly selective aldosterone synthase inhibitor for the treatment of hypertension, part of Corxel's cardiometabolic pipeline.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierKey Regional PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

Everest Medicines acquired Greater China rights to LNZ100/VIZZ (presbyopia treatment) from CORXEL in June 2026. CORXEL eligible to receive up to $85M in regulatory and sales milestones plus tiered mid single-digit to low double-digit royalties on net sales. NDA submitted in China September 2025, expected approval Q1 2027.

Strategic tierKey Regional PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-01
Description

Everest Medicines acquired Greater China rights to develop, manufacture, and commercialize CARDAMYST (etripamil) nasal spray from CORXEL in March 2026, paying $30M upfront plus up to $20M in milestone payments. Everest has a strong cardiovascular franchise and commercialization platform in China targeting 3–6 million PSVT patients.

3Vincentage Pharma
Strategic tierCore Pipeline PartnerTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

CORXEL licensed worldwide ex-Greater China rights to CX11/VCT220 (oral GLP-1 RA) from Vincentage in December 2024. Vincentage retained Greater China rights and is conducting Phase 3 in China. Vincentage reported 12.4% weight loss at 52 weeks in China Phase 3 (May 2026). CORXEL is conducting Phase 2 in the U.S. and Phase 2 in T2DM globally.

fiercebiotech.com
Strategic tierLicensed Asset PartnerTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

CORXEL acquired global rights (excluding Japan) to JX10 (formerly BIIB131) from Biogen in January 2024. TMS Co. retains Japan rights and will collaborate with CORXEL through a Joint Development Committee to advance the global registrational trial.

Strategic tierLicensed Asset PartnerTypeStrategic or Co-development PartnerAnnounced on2022-04-01
Description

CORXEL acquired Greater China rights to LNZ100 (aceclidine eye drops, brand name VIZZ in the U.S.) from LENZ Therapeutics in April 2022. LNZ100 received U.S. FDA approval in July 2025. CORXEL subsequently sold Greater China rights to Everest Medicines in June 2026 for up to $85M in milestones plus royalties.

Strategic tierLicensed Asset PartnerTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

CORXEL entered into an exclusive license agreement with Milestone Pharmaceuticals in May 2021 for development and commercialization of etripamil nasal spray for PSVT and other cardiovascular indications in Greater China. CARDAMYST received FDA approval in December 2025. CORXEL subsequently sold these rights to Everest Medicines in March 2026.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Hansoh Pharmaceutical Group
TypeRegional player
Description

China-based pharmaceutical company with a growing cardiometabolic pipeline including innovative diabetes and obesity therapies. Operates primarily in the Greater China market and represents a comparable regional commercialization model and pipeline focus for Corxel's CX11.

TypeBroad incumbent
Description

Global pharmaceutical leader with an acute ischemic stroke franchise (tenecteplase/Activase) and broader cardiometabolic pipeline. Relevant as a large-cap incumbent competing against Corxel's JX10 in the AIS treatment window-expansion indication.

TypeEmerging player
Description

China-based clinical-stage biotech developing ecnoglutide, a long-acting GLP-1 receptor agonist for diabetes and obesity. Comparable to Corxel's CX11 in modality and target indication within the China cardiometabolic market; represents direct regional competition.

TypeBroad incumbent
Description

Global pharmaceutical leader with the dominant injectable GLP-1 franchise (Mounjaro/Zepbound, tirzepatide) and a Phase 3 oral GLP-1 candidate (orforglipron). Represents the benchmark incumbent Corxel must compete against in the cardiometabolic / obesity market.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, including oral and subcutaneous dual GLP-1/GIP receptor agonists (VK2735). Directly comparable to Corxel on cardiometabolic focus, GLP-1 mechanism, and clinical-stage obesity pipeline.

TypeBroad incumbent
Description

Global leader in diabetes and obesity care with semaglutide (Ozempic/Wegovy) and the only currently marketed oral GLP-1 (Rybelsus). The company's deep cardiometabolic commercial infrastructure and pipeline set the standard Corxel's CX11 must beat or partner against. Corxel's CMO Bo Liang led global development of Semaglutide and Icodec at Novo Nordisk.

TypeDirect peer
Description

Clinical-stage biopharma developing oral small molecule therapies for obesity (TERN-601, oral GLP-1 RA) and other chronic diseases. Direct competitor to Corxel's CX11 in the oral GLP-1 cardiometabolic space with comparable modality and indication focus.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and cardiometabolic disease. Closest direct competitor to Corxel's CX11 in the oral non-peptide GLP-1 space, with similar target indication focus and comparable Phase 2 weight-loss data.

TypeEmerging player
Description

China-based biopharmaceutical company developing mazdutide (dual GLP-1/glucagon receptor agonist) for obesity and diabetes, with NMPA approvals in China. A key Asia-Pacific competitor to Corxel's CX11 in the cardiometabolic space and a potential partner given overlapping China-focused development infrastructure.

TypeBroad incumbent
Description

Global pharmaceutical incumbent developing oral GLP-1 candidates (e.g., danuglipron) for obesity and cardiometabolic disease. Relevant as a large-cap incumbent competing in the same oral GLP-1 category as CX11, with vastly greater commercial scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corxel Pharmaceuticals

Cardiometabolic Therapeuticscorxelbio.com

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for cardiometabolic diseases — including CX11 (oral GLP-1 RA for obesity/T2DM) and JX10 (plasminogen modulator for acute ischemic stroke) — serving global patient populations via a tri-regional US/China/Europe development platform backed by RTW Investments and Bayer.

What Corxel Pharmaceuticals does

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2019 by RTW Investments and headquartered in Berkeley Heights, New Jersey, with operational offices in Shanghai, Hong Kong, Beijing, and Denmark. The company is developing oral small-molecule therapies for cardiometabolic diseases — the leading global cause of death and disability — with a pipeline spanning obesity/overweight, type 2 diabetes mellitus (T2DM), acute ischemic stroke (AIS), and hypertension.

The core proprietary asset is CX11 (VCT220), an oral small-molecule GLP-1 receptor agonist licensed ex-China from Vincentage Pharma in December 2024. CX11 is designed for once-daily administration without food/water restrictions or cold-chain storage, demonstrated 11.5% body weight reduction at 36 weeks in a 246-patient U.S. Phase 2 trial and 12.2–12.4% at 52 weeks in a 840-patient China Phase 3, with favorable GI tolerability and no hepatic safety signal across 1,500+ participants. The pipeline also includes JX10 (formerly BIIB131), a plasminogen modulator licensed from Biogen in January 2024 in a global Phase 2/3 registrational trial for AIS that extends the treatment window from the standard 4.5-hour t-PA limit to 4.5–24 hours from last known well, plus preclinical CX12 (oral amylin receptor agonist) and JX09 (aldosterone synthase inhibitor for hypertension). The cardiometabolic focus has been sharpened by divesting non-core Greater China rights to CARDAMYST (etripamil, to Everest Medicines, March 2026, $30M upfront plus $20M milestones) and LNZ100/VIZZ (presbyopia, to Everest Medicines, June 2026, up to $85M in milestones plus royalties).

The business model is licensing-and-development rather than commercial sales: the company is pre-revenue with no approved products, monetizing assets through upfront and milestone payments from regional partners (Everest Medicines for Greater China commercialization of in-licensed assets) while retaining global rights to its proprietary pipeline for future commercialization or strategic partnership. Capital is sourced from a syndicate of healthcare-specialist investors including RTW Investments (founder), Bayer ($35M equity, January 2024, with privileged CV/ophthalmology negotiation rights), and a $287M Series D1 (January 2026) led by SR One and TCGX with participation from RA Capital, HBM Healthcare Investments, and others. Leadership brings direct lineage to the GLP-1 franchise: CMO Bo Liang led global clinical development of Semaglutide and Icodec at Novo Nordisk, and CFO Kevin Xie previously led Gracell Biotechnologies through its Nasdaq IPO and $1.2B AstraZeneca acquisition.

Corxel Pharmaceuticals firmographics

Firmographics
Name
Corxel Pharmaceuticals
Legal name
Corxel Pharmaceuticals (Shanghai) Co., Ltd. (箕星药业科技(上海)有限公司)
Website
https://corxelbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for cardiometabolic diseases — including CX11 (oral GLP-1 RA for obesity/T2DM) and JX10 (plasminogen modulator for acute ischemic stroke) — serving global patient populations via a tri-regional US/China/Europe development platform backed by RTW Investments and Bayer.
Ownership category
akta.pro rank

Corxel Pharmaceuticals industry classification

Industry
Product category
Cardiometabolic Therapeutics
NAICS
Medical Laboratories (621511)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization

Keywords

  • Clinical-stage biopharmaceutical
  • Cardiometabolic disease therapies
  • Oral small molecule drugs
  • GLP-1 receptor agonists
  • Acute ischemic stroke treatment

Where Corxel Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Berkeley Heights
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Corxel Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing and Asset Monetization: CORXEL generates near-term value through licensing and asset sale transactions. The company sold Greater China rights to LNZ100/VIZZ to Everest Medicines (June 2026) and CARDAMYST to Everest Medicines (March 2026), receiving upfront payments and milestone payments. This model funds the global development of its proprietary cardiometabolic pipeline.
  2. Future Product Sales (Pre-Revenue): CORXEL is a clinical-stage biopharma with no current product revenue. Its proprietary pipeline (CX11 for obesity/T2DM, JX10 for AIS, CX12 in preclinical) is under development globally, with plans to commercialize upon regulatory approval. The company is backed by $287M Series D1 financing to fund development costs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Corxel Pharmaceuticals product offering

Product offering

Core offering

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule therapies for cardiometabolic diseases. Its lead asset CX11 is an oral GLP-1 receptor agonist for obesity, overweight, and Type 2 Diabetes, supported by Phase 2 U.S. and Phase 3 China data. The company also advances JX10, a thrombolytic/anti-inflammatory agent for acute ischemic stroke, and preclinical candidates CX12 (oral amylin RA) and JX09 (aldosterone synthase inhibitor) for hypertension.

Product overview

CORXEL is a clinical-stage biopharmaceutical company developing a portfolio of oral small molecule compounds for cardiometabolic diseases. The core pipeline includes CX11 (oral GLP-1 RA for obesity, overweight, and T2DM), JX10 (thrombolytic agent for acute ischemic stroke), CX12 (amylin RA in preclinical stage), and JX09 (aldosterone synthase inhibitor for hypertension). The company previously held rights to LNZ100/VIZZ (presbyopia treatment) and CARDAMYST (etripamil, PSVT treatment) which were sold to Everest Medicines, allowing CORXEL to focus entirely on its cardiometabolic pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • CX11 (VCT220) Investigational oral small molecule GLP-1 receptor agonist designed for once-daily administration in adults with obesity, overweight with comorbidities, and Type 2 Diabetes Mellitus. Licensed worldwide ex-Greater China from Vincentage Pharma in December 2024.
  • JX10 (formerly BIIB131) Investigational plasminogen modulator with thrombolytic, anti-inflammatory, and antioxidative activities for acute ischemic stroke (AIS), designed to extend the treatment window from the standard 4.5 hours to 4.5–24 hours from last known well. Licensed globally excluding Japan from Biogen.
  • CX12 Investigational oral small molecule amylin receptor agonist in preclinical development for obesity. Designed to regulate satiety, slow gastric emptying, and suppress post-prandial glucagon, with advantages in stability, manufacturing cost, and cold-chain-free storage versus peptide amylin agonists.
  • JX09 Highly selective aldosterone synthase inhibitor for the treatment of hypertension, part of Corxel's cardiometabolic pipeline.

Quantifiable outcome

  • Up to 11.5% body weight reduction at 36 weeks with CX11 (120–200 mg daily oral) in 246 U.S. Phase 2 trial participants with obesity/overweight
  • +4 more outcomes

Companies that use Corxel Pharmaceuticals

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Corxel Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Corxel Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered key regional partner, core pipeline partner and licensed asset partner.

  • Everest Medicineskey regional partnerChannel Partner/ Reseller/ Distributor · 1 June 2026Everest Medicines acquired Greater China rights to LNZ100/VIZZ (presbyopia treatment) from CORXEL in June 2026. CORXEL eligible to receive up to $85M in regulatory and sales milestones plus tiered mid single-digit to low double-digit royalties on net sales. NDA submitted in China September 2025, expected approval Q1 2027.
  • Everest Medicineskey regional partnerChannel Partner/ Reseller/ Distributor · 1 March 2026Everest Medicines acquired Greater China rights to develop, manufacture, and commercialize CARDAMYST (etripamil) nasal spray from CORXEL in March 2026, paying $30M upfront plus up to $20M in milestone payments. Everest has a strong cardiovascular franchise and commercialization platform in China targeting 3–6 million PSVT patients.
  • Vincentage Pharmacore pipeline partnerStrategic or Co-development Partner · 1 December 2024CORXEL licensed worldwide ex-Greater China rights to CX11/VCT220 (oral GLP-1 RA) from Vincentage in December 2024. Vincentage retained Greater China rights and is conducting Phase 3 in China. Vincentage reported 12.4% weight loss at 52 weeks in China Phase 3 (May 2026). CORXEL is conducting Phase 2 in the U.S. and Phase 2 in T2DM globally.
  • Biogenlicensed asset partnerStrategic or Co-development Partner · 1 January 2024CORXEL acquired global rights (excluding Japan) to JX10 (formerly BIIB131) from Biogen in January 2024. TMS Co. retains Japan rights and will collaborate with CORXEL through a Joint Development Committee to advance the global registrational trial.
  • LENZ Therapeuticslicensed asset partnerStrategic or Co-development Partner · 1 April 2022CORXEL acquired Greater China rights to LNZ100 (aceclidine eye drops, brand name VIZZ in the U.S.) from LENZ Therapeutics in April 2022. LNZ100 received U.S. FDA approval in July 2025. CORXEL subsequently sold Greater China rights to Everest Medicines in June 2026 for up to $85M in milestones plus royalties.
  • Milestone Pharmaceuticalslicensed asset partnerStrategic or Co-development Partner · 1 May 2021CORXEL entered into an exclusive license agreement with Milestone Pharmaceuticals in May 2021 for development and commercialization of etripamil nasal spray for PSVT and other cardiovascular indications in Greater China. CARDAMYST received FDA approval in December 2025. CORXEL subsequently sold these rights to Everest Medicines in March 2026.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Corxel Pharmaceuticals competitors and assessment

Company assessment

Regional players

  • Hansoh Pharmaceutical Group: China-based pharmaceutical company with a growing cardiometabolic pipeline including innovative diabetes and obesity therapies. Operates primarily in the Greater China market and represents a comparable regional commercialization model and pipeline focus for Corxel's CX11.

Broad incumbents

  • Roche: Global pharmaceutical leader with an acute ischemic stroke franchise (tenecteplase/Activase) and broader cardiometabolic pipeline. Relevant as a large-cap incumbent competing against Corxel's JX10 in the AIS treatment window-expansion indication.
  • Eli Lilly and Company: Global pharmaceutical leader with the dominant injectable GLP-1 franchise (Mounjaro/Zepbound, tirzepatide) and a Phase 3 oral GLP-1 candidate (orforglipron). Represents the benchmark incumbent Corxel must compete against in the cardiometabolic / obesity market.
  • Novo Nordisk: Global leader in diabetes and obesity care with semaglutide (Ozempic/Wegovy) and the only currently marketed oral GLP-1 (Rybelsus). The company's deep cardiometabolic commercial infrastructure and pipeline set the standard Corxel's CX11 must beat or partner against. Corxel's CMO Bo Liang led global development of Semaglutide and Icodec at Novo Nordisk.
  • Pfizer: Global pharmaceutical incumbent developing oral GLP-1 candidates (e.g., danuglipron) for obesity and cardiometabolic disease. Relevant as a large-cap incumbent competing in the same oral GLP-1 category as CX11, with vastly greater commercial scale.

Emerging players

  • Sciwind Biosciences: China-based clinical-stage biotech developing ecnoglutide, a long-acting GLP-1 receptor agonist for diabetes and obesity. Comparable to Corxel's CX11 in modality and target indication within the China cardiometabolic market; represents direct regional competition.
  • Innovent Biologics: China-based biopharmaceutical company developing mazdutide (dual GLP-1/glucagon receptor agonist) for obesity and diabetes, with NMPA approvals in China. A key Asia-Pacific competitor to Corxel's CX11 in the cardiometabolic space and a potential partner given overlapping China-focused development infrastructure.

Direct peers

  • Viking Therapeutics: Clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, including oral and subcutaneous dual GLP-1/GIP receptor agonists (VK2735). Directly comparable to Corxel on cardiometabolic focus, GLP-1 mechanism, and clinical-stage obesity pipeline.
  • Terns Pharmaceuticals: Clinical-stage biopharma developing oral small molecule therapies for obesity (TERN-601, oral GLP-1 RA) and other chronic diseases. Direct competitor to Corxel's CX11 in the oral GLP-1 cardiometabolic space with comparable modality and indication focus.
  • Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and cardiometabolic disease. Closest direct competitor to Corxel's CX11 in the oral non-peptide GLP-1 space, with similar target indication focus and comparable Phase 2 weight-loss data.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Corxel Pharmaceuticals social profiles

Digital presence

Corxel Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corxel Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

Corxel Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corxel Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corxel Pharmaceuticals

What does Corxel Pharmaceuticals do?

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule therapies for cardiometabolic diseases. Its lead asset CX11 is an oral GLP-1 receptor agonist for obesity, overweight, and Type 2 Diabetes, supported by Phase 2 U.S. and Phase 3 China data. The company also advances JX10, a thrombolytic/anti-inflammatory agent for acute ischemic stroke, and preclinical candidates CX12 (oral amylin RA) and JX09 (aldosterone synthase inhibitor) for hypertension.

Is Corxel Pharmaceuticals a public or private company?

Corxel Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Corxel Pharmaceuticals founded?

Corxel Pharmaceuticals was founded in 2019. It employs 51 to 100 people.

Where is Corxel Pharmaceuticals based?

Corxel Pharmaceuticals is headquartered in Berkeley Heights, United States, in the North America region.

How does Corxel Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Licensing and Asset Monetization is the primary driver. The others are future Product Sales (Pre-Revenue).

Who are Corxel Pharmaceuticals's main competitors?

Hansoh Pharmaceutical Group is listed as a regional player. Broad incumbents are Roche, Eli Lilly and Company, Novo Nordisk and Pfizer. Emerging players are Sciwind Biosciences and Innovent Biologics. Direct peers are Viking Therapeutics, Terns Pharmaceuticals and Structure Therapeutics.

Does Corxel Pharmaceuticals have an API?

No public API is recorded for Corxel Pharmaceuticals.

What industry is Corxel Pharmaceuticals in?

Corxel Pharmaceuticals's product category is Cardiometabolic Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 621511 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAmanat Acquisition 3Q 2026: Net loss ($1.48M) — 10-Q SummaryAmanat Acquisition reported a net loss of $1.48 million in the third quarter of 2026, driven by $2.1 million in formation and administrative costs and $112,050 in share-based compensation, offset by $681,207 in interest earned. The company signed an agreement to combine with Corxel Pharmaceuticals, expected to close in the first half of 2027, and raised $300 million in PIPE financing.The Pharma LetterObesity drug developer Corxel to go public in USA via SPAC dealCorxel Pharmaceuticals and Amanat Acquisition Corp announced a definitive business combination agreement, with Corxel US becoming a wholly owned subsidiary of the combined public company. The combined company will list on Nasdaq under a new ticker, and a new CEO is expected to be hired before or upon closing.FierceBiotechCorxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to NasdaqCorxel Pharmaceuticals agreed in principle to merge with SPAC Amanat Acquisition in the first half of next year, with a $75 million IPO and about $300 million in PIPE financing. The funds will advance its oral GLP-1 drug CX11 through phase 3, with enrollment expected to start in Q1 2026.InvestegateCorxel US to go public via merger with AmanatCorxel US agreed to merge with SPAC Amanat to go public, with expected gross proceeds of about $377 million, including a $300 million PIPE. The combined company will fund its lead obesity drug CX11 through Phase 3, with completion expected in the first half of 2027.TradingViewREG - RTW Biotech Opp. - Corxel US to go public via merger with AmanatCorxel US, part of RTW Bio's Corxel, agreed to merge with SPAC Amanat to go public, with expected gross proceeds of about $377 million including a $300 million PIPE. The combined company will list on Nasdaq, and completion is expected in the first half of 2027. Proceeds will fund CX11 through Phase 3.Nate비만치료제 개발사 코르셀, SPAC 합병 통해 나스닥 상장 추진 : 네이트 뉴스Corxel Pharmaceuticals agreed to merge with SPAC Amanat Acquisition to list on Nasdaq, with a PIPE of about $300 million. The combined funds will support Phase 3 trials of oral GLP-1 drug CX11, which showed 11.5% weight loss in Phase 2. Completion is expected in the first half of 2027.MedCity NewsObesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3Corxel Pharmaceuticals is merging with SPAC Amanat Acquisition Corp. to go public, infusing $377 million. The deal includes a $300 million private placement, with the combined company expected to trade under a new name and symbol. Corxel's lead oral GLP-1 drug CX11 has completed Phase 3 in Asia and is set for Phase 3 in the first half of 2027.BioPharma DiveCorxel, an obesity drugmaker, to go public via SPAC dealCorxel Pharmaceuticals announced plans to go public via a SPAC merger with Amanat Acquisition Corp. and a $300 million private investment. The deal will advance CX11, a GLP-1 pill, into late-stage testing, with a Phase 3 trial potentially starting in Q1 2027.YahooCorxel, an obesity drugmaker, to go public via SPAC dealCorxel Pharmaceuticals announced plans to go public via a SPAC merger with Amanat Acquisition Corp. and a $300 million private investment. The deal will advance CX11, a GLP-1 pill, into late-stage testing, with a Phase 3 trial potentially starting in Q1 2027.Investing.comObesity drug developer Corxel to go public in US via SPAC dealCorxel Pharmaceuticals will go public in the US via a merger with SPAC Amanat Acquisition Corp, announced Monday. The company expects to receive roughly $377 million from the deal, with institutional investors committed $300 million. The deal is anticipated to close in the first half of 2027, with the combined company likely listing on Nasdaq.